Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Thus, our results demonstrate that activation of Wnt/β-catenin pathway involves an ATM/Chk2- independent PI3K/Akt/GSK-3 cascade in TMZ treated cells and further provides mechanistic basis for the chemoresistance of glioma to TMZ.
|
31758290 |
2019 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
|
29378238 |
2018 |
Glioma
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Germline Genetic Predisposition to Hematologic Malignancy.
|
28297620 |
2017 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Silencing of ATM expression by siRNA technique contributes to glioma stem cell radiosensitivity in vitro and in vivo.
|
28560406 |
2017 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Coherent with in vitro findings, pharmacological inhibition of TERT by costunolide decreased lipid accumulation and elevated ATM expression in heterotypic xenograft glioma mouse model.
|
28833137 |
2017 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Silencing of ataxia-telangiectasia mutated by siRNA enhances the in vitro and in vivo radiosensitivity of glioma.
|
27108486 |
2016 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MutL homolog 1 contributes to temozolomide-induced autophagy via ataxia-telangiectasia mutated in glioma.
|
25646660 |
2015 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our study highlights the coordinated control of glioma cell proliferation and metabolism by ROS through (i) ATM-YAP1-driven apoptotic pathway and (ii) JNK-regulated metabolic adaptation.
|
24810048 |
2014 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation.
|
23620409 |
2013 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein.
|
22257080 |
2012 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J.
|
20869334 |
2010 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we tested the hypothesis that polymorphisms and haplotypes in p53 and ATM could be associated with glioma and meningioma risk.
|
17151932 |
2007 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
ATM expression is therefore heterogeneous in the glioma cells examined.
|
16631604 |
2006 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The relationship between ATM protein expression and radiosensitivity in 3 glioma cell lines was examined.
|
16631604 |
2006 |
Glioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Reduction of ATM in a human glioma cell line lacking DNA-PKcs was accompanied by defective signaling through downstream substrates, post-irradiation.
|
15753361 |
2005 |
Glioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Detection of ATM gene mutation in human glioma cell line M059J by a rapid frameshift/stop codon assay in yeast.
|
12105990 |
2002 |
Glioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Regression analysis revealed a high correlation between ATM protein levels and SF2 for primary glioma cell strains, but not for established GBM cell lines. p53 status failed to predict radiosensitivity.
|
11380241 |
2001 |
Glioma
|
0.600 |
CausalMutation
|
disease |
CGI |
|
|
|
Glioma
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|